Teva Metoprolol Succinate Extended-Release Tablets
Metoprolol Succinate Extended-Release Tablets failed dissolution specifications.
Moderate risk
Taking it may cause temporary or medically reversible health problems. Serious harm is unlikely.
FDA Class II recall · How risk is rated
4 photos
What happened
Teva Pharmaceuticals USA, Inc., of Parsippany, New Jersey, recalled Metoprolol Succinate Extended-Release Tablets because the product failed dissolution specifications. The recall began January 29, 2026, and was added to the FDA's Enforcement Report on February 27, 2026. The tablets were distributed nationwide.
Summary by Recall Canary from the FDA notice.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
Affected if its lot code and NDC are listed under that product.
Metoprolol Succinate Extended-Release Tablets
- Strength
- 200 mg
- NDC
- 45963-678-11
- Lot
- 0686H251
- 0687H251
- 10688H251
- Strength
- 50 mg
- NDC
- 45963-676-11
- 45963-676-96
- Lot
- 0486G251
- 0487G251
- 0488G251
- 0486G252
- 0487G253
- 0488G252
- Strength
- 25 mg
- NDC
- 45963-709-11
- 45963-709-96
- Lot
- 0715J251
- 0716J251
- 0717J251
- 0715J252
- 0716J252
Metoprolol Succinate Extended-Release Tablets, Rx Only
- Strength
- 100 mg
- NDC
- 45963-677-11
- 45963-677-96
- Lot
- 0718J251
- 0729J251
- 0730J251
- 0718J252
- 0729J252
- 0730J252
Details
- Company began the recall
- Sold in
- Nationwide
- Event ID
- 98348
- Recall numbers
- D-0354-2026 to D-0357-2026
- Company
- Teva Pharmaceuticals USA, IncParsippany, New Jersey
- Hazard
- Dissolution failure
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA
In FDA's weekly enforcement report
Listed on Recall Canary
Summary updated
